UroToday22h
APCCC Diagnostics 2025: PSA Relapse: When Do You Need to Act?
(UroToday.com) The Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics 2025, held in Lugano, Switzerland, on February 27 th and 28 th, was host to a session addressing the contemporary ...
Renal & Urology News11d
Missing PSA Doubling Time Detrimental in Biochemically Recurrent Prostate Cancer
PSA doubling time is an essential criterion for high-risk biochemically recurrent prostate cancer that should prompt treatment escalation.
UroToday22h
APCCC Diagnostics 2025: Genomic Classifiers at the Time of Biochemical Recurrence
(UroToday.com) The Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics 2025 held in Lugano, Switzerland was host to a session addressing the contemporary management of biochemically ...
ascopubs.org10d
Quantifying the benefit of salvage radiation versus surveillance for biochemically recurrent prostate cancer after radical prostatectomy.
Differences in incidence and clinicopathologic features of secondary bladder cancer after long-term follow-up of brachytherapy and radical prostatectomy for localized prostate cancer. Evaluation of ...